OverviewSuggest Edit

Bionik Laboratories is a medical device and robotics company developing transformational robotic rehabilitation technologies for individuals with neurological disorders. The Company is dedicated to providing individuals with restricted mobility an improvement in overall health, comfort, accessibility, and quality of life through the commercialization of its proprietary products. The Company’s lead program, ARKE is the most comprehensive lower-body exoskeleton that allows paraplegics and as well as other wheelchair users the ability to rehabilitate through walking. Currently, in clinical development, ARKE will initially be used in a rehabilitation environment, with the goal of being made available for home use.
TypePublic
Founded2009
HQToronto, CA
Websitebioniklabs.com
Employee Ratings1.6

Latest Updates

Employees (est.) (Jun 2021)13(-53%)
Revenue (FY, 2021)$1.2 M(+21%)
Share Price (Nov 2021)$2
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Bionik Laboratories

Michael Prywata

Michael Prywata

Co-Founder and Chief Technology Officer, Director
Andre Auberton-Herve

Andre Auberton-Herve

Chairman of the Board
Loren Wass

Loren Wass

Chief Commercial Officer
Richard Russo

Richard Russo

Chief Financial Officer
Remi Gaston-Dreyfus

Remi Gaston-Dreyfus

Director
Peter Gerald Malone

Peter Gerald Malone

Director
Show more

Bionik Laboratories Office Locations

Bionik Laboratories has offices in Toronto and Watertown
Toronto, CA (HQ)
483 Bay St
Watertown, MA, US
80 Coolidge Hill Rd
Show all (2)

Bionik Laboratories Financials and Metrics

Bionik Laboratories Revenue

Bionik Laboratories's revenue was reported to be $1.19 m in FY, 2021
USD

Revenue (FY, 2021)

1.2m

Gross profit (FY, 2021)

923.8k

Gross profit margin (FY, 2021), %

77.4%

Net income (FY, 2021)

(13.6m)

EBIT (FY, 2021)

(13.3m)

Market capitalization (10-Nov-2021)

10.0m

Closing stock price (10-Nov-2021)

2.0

Cash (31-Mar-2021)

600.0k

EV

12.7m
Bionik Laboratories's current market capitalization is $10 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Revenue

7.5k5.2k6.0k571.9k987.4k1.2m

Cost of goods sold

7.0k388.8k402.7k1.6m893.4k269.6k

Gross profit

(1.0k)183.2k584.8k923.8k

Gross profit Margin, %

(17%)32%59%77%
Quarterly
USDQ3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

3.5k15.0k1.2k1.0k1.5k1.5k1.5k1.5k164.2k18.3k372.4k87.5k221.8k261.0k

Cost of goods sold

58.9k12.0k334.8k29.3k59.8k88.4k253.2k384.1k450.3k

Gross profit

105.3k6.3k37.6k58.2k162.0k172.6k

Gross profit Margin, %

64%34%10%67%73%66%
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Cash

12.5k4.9k4.4k3.2k6.6m5.4m543.7k507.3k446.8k2.3m600.0k

Accounts Receivable

125.2k212.7k1.5m847.0k451.9k

Prepaid Expenses

188.2k231.7k433.7k1.4m1.6m1.7m

Inventories

228.2k237.4k405.7k1.1m692.2k
Quarterly
USDQ3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

8.0k10.6k15.6k567.01.5k3.0k5.9k7.3k8.8k6.1m9.1m7.9m2.7m1.7m581.0k846.4k136.1k998.7k959.7k305.8k375.1k

Accounts Receivable

79.0120.4k93.9k253.8k134.9k37.2k306.6k370.2k517.8k1.5m

Prepaid Expenses

158.4k164.4k128.0k188.4k157.1k153.0k172.1k169.3k145.0k485.4k851.2k1.8m

Inventories

260.3k294.0k194.6k255.5k231.4k302.4k155.8k192.6k335.6k
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020FY, 2021

Net Income

(4.7k)(9.4k)(13.1k)(29.5k)(5.6m)(1.0m)(3.9m)(14.6m)10.6m(13.6m)

Depreciation and Amortization

59.5k14.4k629.9k412.9k348.2k380.6k189.7k

Inventories

(39.4k)(9.2k)(168.2k)(653.8k)332.5k

Accounts Payable

(1.5k)16.3k(174.2k)186.2k(332.0k)(60.1k)424.2k(291.8k)(407.9k)
Quarterly
USDQ3, 2011Q1, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

1.3k(1.9k)2.8k(2.9k)(8.7k)(10.5k)(917.0)(4.5k)(5.9k)(7.6m)(9.1m)(4.8m)(2.3m)(1.6m)(2.4m)(2.2m)(5.9m)(8.4m)(760.7k)4.7m7.1m

Depreciation and Amortization

10.4k27.4k42.9k10.2k33.8k57.8k24.6k48.4k69.6k17.6k34.2k50.2k

Inventories

(71.4k)(191.5k)(120.9k)(27.3k)(3.2k)(74.2k)81.6k44.8k(98.2k)

Accounts Payable

2.3k3.4k(71.8k)(111.9k)(178.2k)(703.5k)(696.9k)(718.3k)104.6k172.6k10.1k11.5k181.8k669.8k
USDQ3, 2011

Financial Leverage

4 x
Show all financial metrics

Bionik Laboratories Cybersecurity Score

Cybersecurity ratingPremium dataset

A

92/100

SecurityScorecard logo

Bionik Laboratories Online and Social Media Presence

Embed Graph

Bionik Laboratories Company Culture

  • CEO Rating

    A-

    80/100

Learn more on Comparably

Bionik Laboratories News and Updates

Medical Exoskeletons Market Comprehensive Study Explores Huge Growth in Future | Cyberdyne, Ekso Bionics, Rewalk Robotics, Bionik Laboratories, Rex Bionics

Stay up-to-date with Medical Exoskeletons market research offered by HTF MI. Check how key trends and emerging drivers are shaping this industry growth. Posted via Industry Today. Follow us on Twitter @IndustryToday

Robotic Rehabilitation and Assistive Technologies Market is Anticipated to grow at a CAGR by 2025- Accuray Incorporated, AlterG, Inc., Bionik Laboratories Corp., DIH Technologies Corporation

Rehabilitation robotics is a field of research dedicated to understanding and augmenting rehabilitation through the application of robotic devices. Posted via Industry Today. Follow us on Twitter @IndustryToday

Bionik Laboratories Files Registration Statement for Proposed Follow-On Offering

TORONTO and BOSTON, Oct. 30, 2018 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB: BNKL) ("Bionik" or the "Company"), a pioneering healthcare company combining artificial intelligence and innovative robotics technology to help individuals from hospital to home to regain mobility,...

Bionik Laboratories Appoints Dr. Audrey D. Thévenon and Charles Matine to its Board of Directors

TORONTO and BOSTON, Sept. 13, 2018 /PRNewswire/ -- Bionik Laboratories Corp. (OTCQB: BNKL) ("Bionik" or the "Company"), a pioneering healthcare company combining artificial intelligence and innovative robotics technology to help individuals from hospital to home to regain mobility,...

Bionik Laboratories Blogs

BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry

Company to Showcase its InMotion® Robotic Therapy Systems at the World’s Largest Medical Industry Event TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology s…

BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results

$5 Million Capital Raise Strengthens Balance Sheet TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to…

BIONIK Laboratories Announces Commercial Team Addition With Newly Hired Regional Sales Director, Tony Bellofatto

Company Placing Renewed Emphasis on the Country’s ‘Stroke Belt’, Increasing its Commitment to Address the Growing Needs of Stroke Patients TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabi…

BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform

Company also reports three consecutive quarters of patient session growth as U.S. healthcare facilities continue to adopt innovative technologies to accelerate stroke recovery TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK" or the "Company"), a robotics…

BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes

TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, announced today it has entered into a series o…

BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO

TORONTO & BOSTON--(BUSINESS WIRE)-- BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today has announced that Chief Executive Offic…
Show more

Bionik Laboratories Frequently Asked Questions

  • When was Bionik Laboratories founded?

    Bionik Laboratories was founded in 2009.

  • Who are Bionik Laboratories key executives?

    Bionik Laboratories's key executives are Michael Prywata, Andre Auberton-Herve and Loren Wass.

  • How many employees does Bionik Laboratories have?

    Bionik Laboratories has 13 employees.

  • What is Bionik Laboratories revenue?

    Latest Bionik Laboratories annual revenue is $1.2 m.

  • What is Bionik Laboratories revenue per employee?

    Latest Bionik Laboratories revenue per employee is $91.8 k.

  • Who are Bionik Laboratories competitors?

    Competitors of Bionik Laboratories include Distalmotion, Neocis and Freehand.

  • Where is Bionik Laboratories headquarters?

    Bionik Laboratories headquarters is located at 483 Bay St, Toronto.

  • Where are Bionik Laboratories offices?

    Bionik Laboratories has offices in Toronto and Watertown.

  • How many offices does Bionik Laboratories have?

    Bionik Laboratories has 2 offices.